Breast cancer is the most common type of cancer among women worldwide, and metastasis represents the most devastating stage of the disease. Recent studies have revealed that microRNAs (miRNA) have critical roles to regulate cancer cell invasion and metastasis. Here we present evidence to show the role of miR-182 in breast cancer metastasis. miR-182 is upregulated in the malignant cell line variants of both human MCF10 and mouse 4T1 series. Ectopic expression of miR-182 enhanced breast cancer cell motility and invasiveness, whereas miR-182 inhibition resulted in opposite changes. In nude mice, miR-182 led to increased pulmonary colonization of cancer cells. We further demonstrated that miR-182 directly targets MIM (Missing in Metastasis), which suppresses metastasis by inhibiting ras homolog family member A (RhoA) activity and stress fiber formation in breast cancer cells. Restoring MIM expression completely blocked the pro-metastasis function of miR-182, while RhoA inhibition reversed the phenotypes of both miR-182 overexpression and MIM knockdown. In breast tumor samples, miR-182 induction is linked to downregulation of MIM, RhoA activation and poor prognosis. Hence, our data delineates the molecular pathway by which miR-182 promotes breast cancer invasion and metastasis, and may have important implication for the treatment of metastatic cancers.
INTRODUCTION
Breast cancer is worldwide the leading cancer for women, in terms of both incidence and mortality. 1 Metastasis of breast cancer cells to bone, lung and other vital organs is responsible for the majority of cancer deaths. Despite years of studies, the molecular underpinnings of breast cancer metastasis remain incompletely understood.
MicroRNAs (miRNAs) are a cluster of non-coding RNA molecules ranging in size from 19 to 24 nucleotides and suppress target gene expression by initiating mRNA degradation and/or blocking translation. Recently, the miRNA molecule miR-182 has been noticed for its roles in the regulation of mammalian circadian rhythm, T-cell development and DNA repair. [2] [3] [4] [5] In cancer, miR-182 was found to contribute to the oncogenic state of MCF7 breast cancer cells, 6 but suppress the tumorigenesis of lung adenocarcinoma. 7 The pro-metastatic trait of miR-182 was first studied in melanoma, where its overexpression promoted cell migration and survival. 8 Another study by the same group demonstrated that sustained miR-182 suppression prevented liver metastasis of melanoma cells in mice. 9 miR-182 expression has also been linked to glioma progression and poor survival of patients. 10 Furthermore, it was recently reported that miR-182 was overexpressed in high-grade ovarian papillary serous carcinoma and contributed to tumorigenesis and cancer progression. 11 However, the role of miR-182 in breast cancer metastasis remains unknown.
MIM (Missing in Metastasis)
, also named as MTSS1, is a gene that is involved in sonic hedgehog 12, 13 and epidermal growth factor signaling, 14 and also acts as a scaffold protein to regulate cytoskeleton. [15] [16] [17] [18] [19] The involvement of MIM in cancer metastasis was initially suggested when it was found to be silenced in the metastatic bladder cancer cell line TCCSUP. 20 Several follow-up studies then showed its downregulation linked to the progression and poor prognosis of various cancers. [21] [22] [23] [24] However, other reports observed inconsistent patterns of MIM expression in cancer progression and metastasis. [25] [26] [27] [28] In addition, there are only a few in vitro studies to characterize its function in cancer cell invasion and the results were contradictory. 22, 29 Parr et al. 22 showed that MIM overexpression suppressed the migration and invasion of MCF7 breast cancer cells, whereas Du et al. 29 reported that MIM overexpression did not result in such changes in bladder cancer cells. Therefore, these recent studies have raised serious doubts about the role and potential therapeutic utility of MIM in cancer metastasis. 27, 28, 30 Furthermore, it remains unexplored how MIM might regulate metastasis-related processes.
In this study we present the evidence to show that miR-182 promotes tumor cell invasion and metastasis by suppressing MIM in breast cancer. In addition, MIM inhibits stress fiber formation and invasion of cancer cells through inactivation of the cytoskeleton regulator RhoA. Therefore, our data demonstrated that MIM is indeed a metastasis suppressor in breast cancer, and the study also shed light on the molecular mechanisms of its antimetastasis function.
RESULTS miR-182 is positively correlated to breast cancer metastasis and enhances cell migration and invasion To study miR-182 in breast cancer metastasis, we first assessed its expression in the 4T1 and MCF10 series of breast cancer cell lines. The 4T1 series cell lines, including 67NR, 168FARN, 4TO7 and 4T1, were all derived from a spontaneous mouse mammary tumor. 31, 32 Among them, only 4TO7 and 4T1 could disseminate to the lung, and 4T1 gave rise to macroscopic metastases when inoculated orthotopically into the mice. The human MCF10 series consist of MCF10A, MCF10AT, MCF10CA1h and MCF10CA1a, of which MCF10A is an immortalized normal mammary epithelial cell line, and the other three were derived from MCF10A with gradually increased malignancy. MCF10AT cell could form benign hyperplasia and progress into carcinoma in immunodeficient mice. MCF10CA1h produced largely well-differentiated carcinoma, whereas MCF10CA1a led to poorly differentiated carcinoma and rapidly formed lung metastasis in tail vein injection assay. 33, 34 We found that miR-182 was expressed significantly higher in 4TO7 and 4T1 than in 67NR and 168FARN. miR-182 expression was also progressively elevated in the three MCF10 cancer cell lines. However, the expression level of miR-182 in the non-tumorigenic cell line MCF10A was comparable to that in MCF10CA1a ( Figure 1a) . Thus, miR-182 expression was positively correlated to metastasis but not the oncogenic state in these breast cancer cell lines.
Therefore, we explored the functional role of miR-182 in breast cancer cell migration and invasion. The human miR-182 gene was stably overexpressed in 4T1 and MCF10CA1h (Supplementary Figure 1a) . The overexpression significantly enhanced woundhealing migration and transwell invasion in both cell lines (Supplementary Figure 2a; Figures 1b and c) . To further confirm the effects of miR-182, we analyzed two derivative cell lines, SCP28 and LM2, of human MDA-MB-231 (MB231) breast cancer cells. SCP28 has a mild metastasis affinity to the lung, whereas LM2 is highly lung-tropic. 35 The expression of miR-182 was much higher in LM2 than SCP28 (Supplementary Figure 1b) . Thus, we overexpressed miR-182 in SCP28 (Supplementary Figure 1a) and observed markedly elevated migration and invasion of SCP28 cells ( Supplementary Figure 2a; Figures 1b  and c) . We further used an antisense oligonucleotide to inhibit miR-182 and assessed the phenotype by miR-182 silencing. The inhibitor treatment of the miR-182-expressing cancer cells, including 4TO7, MCF10CA1h and LM2, resulted in a marked reduction of cell invasion (Figure 1b) . We also constructed a sponge vector to interrupt the function of miR-182. In MCF10CA1a, miR-182 inhibition by the sponges decreased cell migration (Supplementary Figure 2c) . In addition, it seemed that miR-182 had no effects on cancer cell proliferation, as the cell growth of SCP28 and 4T1 did not show obvious changes after miR-182 overexpression (Supplementary Figure 3a) . miR-182 promotes in vivo lung colonization of breast cancer cells Next we assessed the in vivo functions of miR-182 in breast cancer tumor growth and metastasis. First, we implanted the miR-182-expressing cells and control SCP28 cells into the mammary fat pads of nude mice and did not find significant difference of tumor growth (Supplementary Figure 3b) , a phenomenon consistent with the in vitro observations. Then the SCP28 cells were injected intravenously into the nude mice for lung metastasis analysis, and the mice were examined by bioluminescent imaging (BLI) every week after injection. The lung metastasis burden caused by the miR-182-expressing cancer cells was prominently heavier than that by the control cells. At week 7, the BLI metastasis burden was over 10-folds higher in the animal group of miR-182 overexpression (Figures 1d and e) . When the mice werekilled, nearly 20-fold more tumor nodules were observed on the surfaces of the lungs inoculated by miR-182-expressing cancer cells (Figures 1f  and g ). The difference was also confirmed by histological observation of the organs (Figure 1f ). Kaplan-Meier analysis showed that miR-182 overexpression led to shorter metastasisfree survival of the animals ( Figure 1h ). These analyses demonstrated a pro-metastatic role of miR-182 in breast cancer.
MIM is a direct target of miR-182 Next we aimed to find the target genes of miR-182 to explain its pro-metastatic function. We first performed a bioinformatic screen for its target gene candidates (Figure 2a) . We analyzed the 3 0 UTR (untranslated region)-binding site prediction by TargetScan 36 and PicTar. 37 We also analyzed the global gene expression of MCF10 cells by microarray and assessed the correlation of each gene with miR-182. A total of 245 and 213 genes were predicted to be miR-182 targets by TargetScan and PicTar, respectively, whereas 2886 genes had an expression pattern negatively correlated to that of miR-182 in the MCF10 series with Rho o À 0.8. Overlap analysis revealed 12 genes appearing in all the three gene sets (Supplementary Table 1 ). Among these 12 genes, MIM was of particular interest as previous studies have reported the correlation of its silencing with cancer metastasis. 21, 22, 26, 38 The 3 0 UTR of MIM contains three predicted binding sites of miR-182 at the positions of 262, 1083 and 1928 bp, respectively. To determine whether MIM is a bona fide target of miR-182, the 3 0 UTR DNA fragment containing these three sites was cloned into the pMIR-REPORT vector for luciferase reporter assays. The 3 0 UTR of MITF, a known target gene of miR-182, was used as a positive control. The luciferase activities of both MIM and MITF 3 0 UTRs were significantly reduced upon miR-182 transfection in HeLa and SCP28 cells (Figure 2b ). In addition, the treatment of anti-miR-182 oligonucleotide restored their activities ( Figure 2c ). Therefore, the MIM 3 0 UTR was targeted by miR-182. To investigate which binding sites at the MIM 3 0 UTR contribute to the regulation by miR-182, we cloned each of the binding sites individually into the reporter vector and found that only site 1 (262 bp) and 3 (1928 bp), which are the evolutionally conserved regions among the three sites, showed decreased luciferase activities upon miR-182 transfection (Figure 2d ). In addition, mutating the sequences of site 1 and 3 in the seed regions reversed the miR-182 suppression (Figure 2e ), thus establishing these two regions as the direct target sites of miR-182.
We further analyzed the effect of miR-182 on MIM expression in the cancer cells. Overexpression of miR-182 in SCP28 caused modest but significant attenuation of MIM transcript abundance (Figure 2f ). The suppression of MIM by miR-182 was more manifest at the protein level (Figure 2g ). The miR-182 target sites at the 3 0 UTR of MIM were well conserved in human and mouse (Supplementary Figure 2d) , suggesting that human miR-182 might also be able to target the mouse MIM gene. Indeed, overexpression of human miR-182 in 4T1 suppressed the expression of endogenous MIM (Figures 2f and g ). Furthermore, treatment of anti-miR-182 oligonucleotide inhibitors or transfection of miR-182 sponges markedly enhanced MIM expression in MCF10CA1a and LM2 (Figure 2h; Supplementary Figure 1d) . Taken together, these data argued that MIM is a direct target of miR-182.
MIM is a breast cancer metastasis suppressor Loss of MIM in malignant cancer cells has been previously reported, but its role in metastasis is yet to be determined. We found that MIM expression was progressively lost in the MCF10 series (Supplementary Figure 1c) . Thus, we overexpressed MIM in MCF10CA1a and SCP28 (Supplementary Figure 1d) and observed obvious repressions of cell motility and invasion (Figure 3a) . Then we examined whether MIM depletion is sufficient to promote the malignant traits of cancer cells using the short-hairpin RNA (shRNA) approach. Two independent shRNA constructs, KD3 and KD6, efficiently silenced MIM expression in MCF7, a non-metastatic cell line expressing MIM abundantly (Supplementary Figures 1c  and d) . Both constructs significantly elevated the motility and invasiveness of MCF7 ( Supplementary Figure 2a; Figure 3b ). We further tested the effect of MIM knockdown in MCF10AT. KD3 silenced the expression of MIM (Supplementary Figure 1d) , and enhanced the migration and invasion of MCF10AT cells as well ( Supplementary Figure 2b; Figure 3b ). However, we were not able to generate the stable derivative line with KD6 in MCF10AT. Therefore, we looked for more effective knockdown constructs in mouse cells. KD3, which targets both human and mouse MIM genes, and KD9, which is specific for mouse MIM, suppressed MIM expression in 4TO7 cells (Supplementary Figure 1d) . Accordingly, Figure 2b) . In addition, MIM silencing led to no changes in growth rates of the cancer cells ( Supplementary  Figure 3c) , which was concordant to the observations after miR-182 overexpression.
To further assess the function of MIM in breast cancer metastasis, we analyzed the in vivo metastasis property of MCF10CA1a cells with MIM overexpression by tail vein injection. BLI quantitation showed that the control cells developed lung metastasis rapidly in nude mice, whereas MIM overexpression completely suppressed the metastatic growth of MCF10CA1a in the animal lungs (Figure 3c) . Such difference was confirmed by the whole-lung visualization and haematoxylin and eosin (H&E) staining of the lung sections (Figure 3d ). Animal deaths in the control group were observed after 12 weeks post injection. However, all mice inoculated with the MIM-expressing cells were alive even 16 weeks later (Figure 3e ). These data evidenced the anti-metastasis role of MIM in breast cancer. Figure 1e) . Interestingly, MIM restoration completely blocked the boost of cell migration and invasion by miR-182 (Figure 3f ).
MIM expression reverses miR-182-promoted metastasis
To ascertain whether MIM can rescue the metastasis phenotype imposed by miR-182, we injected SCP28 cells with miR-182 overexpression only, or with both miR-182 and MIM overexpression into nude mice. Concordant to the previous observations, miR-182 induction promoted lung metastasis burden caused by the cancer cells and impaired the animal survival (Figures 3g-i) . However, such changes were completely abolished by the restoration of MIM in the miR-182-expressing cells. As shown by the histological examination of lung sections, the cells with double overexpression only led to sporadic small lesions in the lungs, a phenomenon similar to the control group. But massive lesions were observed in the animals inoculated with the cells of miR-182 overexpression only (Figure 3h ). The animal survival of the double overexpression group was also comparable to the control group (Figure 3i) . Notably, BLI analysis showed that simultaneous expression of miR-182 and MIM suppressed the metastatic growth of SCP28 cells to a level that was even weaker than the control cells (Figure 3g ), although such difference was not obvious in the analyses of lung histology and animal survival (Figures 3h and i) . The BLI signal difference between the control cells, and the cells with both miR-182 and MIM was concordant to the expression pattern of MIM in these cells (Supplementary Figure 1e) . Taken together, these data suggested that MIM suppression mediates the pro-metastasis function of miR-182.
MIM suppresses stress fiber formation and cell invasion by inactivating RhoA Then we analyzed the molecular mechanism by which MIM suppresses cancer cell invasion and metastasis. Previous studies have shown that MIM functions in cytoskeleton regulation. [16] [17] [18] [19] 28 As cytoskeleton restructuring is an important process involved in cancer cell migration and invasion, we tested whether MIM suppresses cancer metastasis by regulating cytoskeleton. Rhodamine phalloidin staining of F-actin was performed to assess the stress fiber formation, a critical event of cytoskeleton rearrangement during cell migration, and a line profiling method was used to quantitate the stress fibers in cancer cells. 39 The analysis revealed that MIM impaired stress fiber formation in cancer cells. Upon MIM depletion in MCF10AT, the cells were characterized by the presence of considerably more F-actin bundles, that is, stress fibers, across the cytoplasm, whereas induction of MIM decreased the number of stress fibers significantly in MCF10CA1a (Figures 4a-d) . Furthermore, miR-182 overexpression in MCF10CA1h resulted in enhanced stress fiber formation, whereas the treatment of miR-182 inhibitor phenocopied the effect of MIM induction (Figures 4c and d) . The suppressive role of miR-182 inhibitor on stress fiber arrangement was also confirmed in 4TO7 (Supplementary Figure 4a) . These results revealed the roles of MIM and miR-182 in the regulation of breast cancer cell cytoskeleton.
The Rho small GTPases are key mediators of stress fiber formation and cell motility. 40 So we decided to test whether MIM or miR-182 affects Rho activation to regulate cancer cell cytoskeleton. The active Rho pull-down assays showed that both MIM knockdown and miR-182 induction significantly enhanced the active RhoA, but had no effect on the total RhoA level in MCF10 and 4TO7 cell lines. In addition, both MIM induction and miR-182 inhibition downregulated the activation of RhoA (Figure 4e ). In contrast, MIM had no obvious effects on the activation of other small GTPases, including RhoB, RhoC and Rac1 (Supplementary Figure 5) .
Next we assessed whether RhoA mediates the roles of miR-182 and MIM in cancer cell invasion and cytoskeleton rearrangement. We treated the cancer cells of MIM knockdown with the exoenzyme C3 transferase, a specific inhibitor of Rho proteins by ADP-ribosylation on asparagine residue 41 in the effector binding domain of the GTPases, and observed that RhoA inhibition abolished the difference on stress fiber formation caused by MIM silencing in MCF10AT and 4TO7 (Figure 5a ; Supplementary Figure 4b) . Similarly, while miR-182 overexpression increased the number of stress fibers in MCF10CA1h when the cells were not treated, no such difference was seen in the presence of C3 transferase (Figure 5b ). In addition, C3 transferase blocked the effects of miR-182 and its target on cancer cell invasion. When the cancer cells were treated with the Rho inhibitor, the cell invasiveness was markedly attenuated and could not be improved by miR-182 induction, MIM knockdown or overexpression (Figures 5c-e) . We also tested whether the inhibitors of other small GTPases, including Rac1 and Cdc42, could reverse the phenotypes by MIM knockdown and miR-182 induction in MCF10AT and MCF10CA1h cells. Although the Rac1 inhibitor itself was able to suppress the invasive properties of these cells, inhibition of either Rac1 or Cdc42 did not block the pro-invasion phenotype by MIM knockdown or miR-182 overexpression (Supplementary Figure 6) . These results demonstrated that RhoA, but not Rac1 or Cdc42, acts downstream of MIM to mediate the function of miR-182 in cytoskeleton rearrangement and invasion of cancer cells. miR-182 is correlated with poor prognosis and MIM suppression in clinical samples Finally, we investigated the clinical relevance of miR-182 by analyzing the expression of miR-182 in a cohort of breast cancer clinical samples. The expression of miR-182 was significantly higher in the primary tumors that spread to nearby lymph nodes (LN) than in the LN-negative tumors (Figure 6a ). In addition, when the samples were segregated into two groups according to the expression levels of miR-182, the group with elevated miRNA expression displayed higher probabilities of tumor relapse and distant metastasis (Figures 6b and c) . Moreover, we analyzed the levels of MIM and RhoA in these tumor samples, which led to the observation that miR-182 elevation was linked to MIM silencing and enhanced activation of the small GTPase (Figures 6d and e) . These data supported the conclusion that miR-182 targets MIM to promote RhoA activation and metastasis in breast cancer. 
DISCUSSION
Recently miR-182 is emerging as an important regulator of various physiological and pathological processes. [2] [3] [4] 41 Previous studies have also linked the expression of miR-182 to lung cancer, breast cancer, glioma, medulloblastoma and ovarian cancer, 6, 7, 10, 11, 42 although the functional analyses of miR-182 in tumorigenesis have yielded contradictory results in different cancer models. 6, 7, 11 In this study, we extend the study of miR-182 to breast cancer metastasis. We showed that the expression of miR-182 was tightly correlated with metastasis in breast cancer cells, and functionally, the miRNA promoted migration, invasion and lung colonization of breast cancer cells. More importantly, the clinical relevance of miR-182 was confirmed in human breast tumor samples. Therefore, these results firmly established miR-182 as a functional mediator of breast cancer metastasis and a promising therapeutic target to treat the disease. However, miR-182 might function differently in tumorigenesis. We noticed that it was upregulated in the normal epithelial line MCF10A than in the tumorigenic lines MCF10AT and MCF10CA1h, although our tumorigenesis analysis revealed no difference in tumor growth caused by this miRNA. In addition, a previous study showed that miR-182 instead suppressed the proliferation and anchorage-independent growth of lung cancer cells. 7 Thus, the exact role of miR-182 in early stages of malignant progression is yet to be further defined.
In addition, our study revealed the functional mechanism of miR-182 in breast cancer metastasis. miR-182 directly targets MIM and subsequently promotes RhoA activation and the formation of stress fiber, while MIM re-expression completely rescued the miR-182-induced metastasis phenotypes. The RhoA inhibitor was also able to block the effects on cell invasion, and cytoskeleton remodeling resulted from miR-182 overexpression and MIM silencing. In clinical samples, the expression of miR-182 and MIM was negatively correlated. Therefore, the data delineated the signaling pathway by which miR-182 regulates the cytoskeleton dynamics and metastasis properties of breast cancer cells.
MIM was initially considered as a candidate of metastasis suppressor because of the fact that it was silenced in metastatic bladder cancer cells. 20 However, several recent studies reported inconsistent patterns of MIM expression in metastasis. 25, 27, 28 Instead, accumulating evidence indicates that MIM functions as a scaffold protein to interact with actin cytoskeleton proteins. [15] [16] [17] [18] [19] These findings lead to the notion that MIM is unlikely to be a metastasis suppressor, but rather a cytoskeleton regulator. 27, 28, 30 The controversy over the role of MIM in metastasis are at least in part because of the fact that previous cancer studies on MIM have been mainly correlative analyses and comprehensive functional characterizations of MIM, especially in vivo studies, are lacking. 11, 22, 29 Here, we assessed the function of MIM in breast cancer metastasis with approaches of overexpression and knockdown in multiple cell lines of both human and mouse origins. The analyses showed consistently that MIM suppressed migration and metastasis of breast cancer cells by inactivating the cytoskeleton regulator RhoA. Cytoskeleton rearrangement is a critical aspect for cancer cell motility and invasiveness, and many cytoskeleton modulators are involved in cancer metastasis. Therefore, previous studies showing the roles of MIM in cytoskeleton dynamics [15] [16] [17] [18] [19] are not contradictory, but rather in line with the concept that it has a critical role in cancer metastasis.
Overall, we combined experimental analyses and clinical studies to demonstrate the roles and mechanisms of miR-182 and MIM in breast cancer metastasis. The stark differences in the metastatic behaviors of cancer cells caused by these two molecules, especially MIM, and their clinical associations with the prognosis of cancer patients, warrant further clinical studies of these molecules as potential prognostic markers and therapeutic targets.
MATERIALS AND METHODS

Plasmids and reagents
The retroviral plasmid for miR-182 overexpression pMSCV-PIG-miR-182 was a kind gift from Dr Eva Hernando at New York University School of Medicine. 8 The sponge vector was constructed by inserting eight tandemly arrayed miR-182-binding sites (5 0 -AGTGTGAGTTCTAGGGTTTGCCAAA-3 0 ) into the 3 0 UTR of dsRed, which had been previously cloned into pMSCVhygro. 44 For MIM overexpression, the human MIM complementary DNA without 3 0 UTR was cloned into the pMSCV-hygro vector. For MIM knockdown, the sense and antisense shRNA oligonucleotides were annealed and cloned into pSuper-Retro-Puro (OligoEngine, Seattle, WA, USA). Several shRNA constructs were tested for their knockdown efficacy. KD3 and KD6 were proven effective for human MIM gene, whereas KD3 and KD9 were effective for mouse MIM. All the cells with stable overexpression or knockdown of miR-182 and/or MIM were polyclonal derivatives with puromycin or hygromycin selection to avoid clonal variations in functional assays.
For 3 0 UTR reporter assays, a 2.1-kb fragment of MIM 3 0 UTR and a 0.7-kb fragment of MITF 3 0 UTR were cloned into pMIR-Report (Ambion, Austin, TX, USA). Sites 1 and 3 were further mutated to 5 0 -TGAAGGTGGGTAA-3 0 and 5 0 -ATGTTGGGTAA-3 0 , respectively. The sequences of primers and shRNA oligonucleotides used in this study were available in Supplementary  Table 2 .
Other reagents used in the study include rabbit polyclonal MIM antibody (Cell Signaling Technology, Danvers, MA, USA), rabbit anti-human RhoA, RhoB and RhoC (Cell Signaling Technology), C3 transferase covalently linked to a proprietary cell-penetrating moiety (Cat# CT04, Cytoskeleton, Denver, CO, USA) and the Rac1 inhibitor NSC23766 (sc-204823, Santa Cruz, Dallas, TX, USA). The amino acids 17-32 of Cdc42 tagged with the TAT internalization sequence at its C-terminus 45 was synthesized by GL Biochem (Shanghai, China), and the anti-miR-182 oligonucleotide and negative control oligonucleotide were purchased from GenePharma (Shanghai, China).
miRNA detection
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA). Two independent online databases, TargetScan and PicTar, were used to predict miR-182 targets. The genes predicted by TargetScan with no less than two miR-182-binding sites and at least one evolutionarily conserved site, and those predicted by PicTar with the scores higher than the average score of all miR-182 targets were selected as the miR-182 candidate targets. We also analyzed the four cell lines of MCF10 series with the Agilent Whole Human Genome 4 Â 44k microarray, and then calculated the correlation of each gene to miR-182 expression in these cell lines. The genes with a correlation coefficient o À 0.8 were selected. Finally the three analyses were compared to select the genes in common.
Luciferase dual-reporter assays HeLa or SCP28 cells were cotransfected with the control or miR-182-expressing plasmid, the indicated firefly luciferase reporter plasmid and a renilla luciferase plasmid with a ratio of 2:2:1. Lysates were collected 72 h after transfection. Firefly and renilla luciferase activities were measured with a Dual-Luciferase Reporter System (Promega, Fitchburg, WI, USA). At least three biological replicates were used for each sample.
Wound healing and invasion assays
Wound healing and Matrigel invasion assays were performed as previously described. 46 For GTPase inhibitor treatment, C3 transferase (1 mg/ml), NSC23766 (50 mM) or the Cdc42 inhibitor (10 mg/ml) was added into the upper chamber 4 h before the transwell invasion analysis.
Stress fiber analysis
Cancer cells of B30% confluence were starved for 24-48 h depending on the cell lines, and then the cells were fixed with PBS containing 3.7% paraformaldehyde without methanol. The cells were washed and permeabilized with 0.1% Triton X-100 before being stained with Rhodamine phalloidin according to the manufacturer's protocol (Invitrogen). More than 25 individual cells per treatment group were visualized by confocal microscopy (LSM-510META, Carl Zeiss) in each experiment. The numbers of stress fibers in each cell was quantitated as previously described. 39 Briefly, the Image Pro Plus software (Media Cybernetics, Bethesda, MD, USA) was used to generate line profiles for each cell. A graphic depiction was then generated where the x axis represented the distance across the cell, the y axis represented the level of fluorescence and each immunofluorescence intensity spike represented an individual stress fiber crossed by the line. The fluorescence intensity level of 100 was set as the cutoff of stress fiber spike, as the background intensities outside cells were never greater than this value.
Active Rho/Rac1 pull-down assays
The assays were performed with the Active Rho or Rac1 Pull-Down and Detection kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacture's instruction. In brief, cells were lysed by 1 Â lysis buffer and the same amount of total proteins was incubated with agarose beads and GST-Rhotekin-RBD or GST-Pak1 protein-binding domain. After incubation at 4 1C for 1 h, the samples were washed three times with 0.4 ml of 1 Â lysis buffer. Following the last wash, 50 ml 2 Â reducing buffer was added to the samples and incubated at room temperature for 2 min. At last the samples were collected by centrifugation at 6000 g for 2 min and were electrophoresed on a gel followed by western blot analysis.
Animal studies
Primary tumor growth and lung metastasis analyses were performed in female BALB/c nude mice as previously described. 46 Non-invasive BLI was performed using the NightOWL II LB 983 Imaging System (Berthold Technologies, Bad Wildbad, Germany). All the cancer cells used for BLI analysis were labeled with the luciferase-expressing plasmid before genetic modification of miR-182 or MIM to ensure the relatively equal luminescent activities in the tested cell lines, and all BLI intensities were normalized to those at injection. Lung metastasis-free survival curves represent the time point at which each mouse developed lung metastasis as defined by a predetermined threshold BLI signals in lung. 47 Ten mice per group were used for the metastasis analysis.
Clinical analysis
Fresh tumor specimens were obtained from Sun Yat-Sen University Cancer Center with informed consent from all subjects and approval from the Institutional Research Ethics Committee. RNA was extracted from the fresh tumors and the quality was monitored by O.D. reading. Finally, a cohort of 38 specimens with high-quality RNA samples was used for miR-182 analyses of patient survival. These samples were classified into two groups according to the median expression level of miR-182. One of these samples was further removed in the analysis of correlation between miR-182 and MIM due to amplification failure of MIM mRNA. For RhoA activation analyses, another cohort of 10 primary tumor samples was used for protein extraction and pull-down assays, as well as RNA extraction for miR-182 quantitation. One of these samples was removed from the analysis due to unsuccessful protein extraction.
Statistical analysis
The Kaplan-Meier method was used to estimate the survival curves for the mice and patients, and Cox proportional hazard regression was used to compare the survival. Two-sided independent student's t-test without assumption of equal variance was performed to analyze the results of in vitro assays.
